Daiichi Sankyo Co Ltd - Company Profile
Powered by
All the data and insights you need on Daiichi Sankyo Co Ltd in one report.
- Save hours of research time and resources with
our up-to-date Daiichi Sankyo Co Ltd Strategy Report
- Understand Daiichi Sankyo Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Daiichi Sankyo Catalyst Calendar
Proactively evaluate Daiichi Sankyo Co Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Daiichi Sankyo Catalyst Calendar data
Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
---|---|---|---|---|---|---|---|
03 Sep 2019 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
01 Sep 2019 | Phase IV Trial Initiation | Daiichi Sankyo Co Ltd; Hamilton Health Sciences; Population Health Research Institute; St. John’s Academy of Health Sciences | 4568 | edoxaban tosylate | Cardiovascular; Central Nervous System | Atrial Fibrillation; Atrial Flutter; Intracerebral Hemorrhage | Clinical Trial Registry |
31 Aug 2019 | Phase I/II Trial Completion | Daiichi Sankyo Co Ltd; Syneos Health Inc | 4568; SYNH | DS-1040 | Cardiovascular; Hematological Disorders | Acute Ischemic Stroke; Bleeding And Clotting Disorders | Clinical Trial Registry |
25 Aug 2019 | PDUFA | Daiichi Sankyo Co Ltd | 4568 | quizartinib dihydrochloride | Oncology | Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia | Company Press Release |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer